Related Experiment Video
Updated: Jul 18, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
[Utility of vasopressin in cardiopulmonary resuscitation]
A Zabalegui1, M Arroyo, F Callejo
1Servicio de Medicina Intensiva, Complejo Hospitalario General Yagüe, Burgos, España. azaba@hgy.es
Abstract:
Many vasopressants have been studied in cardiopulmonary resuscitation (CPR) to increase cerebral and coronary perfusion. Although there is a debate on the utility of epinephrine, this is the one that has been used historically, above all after verifying that other agents such as norepinephrine, metoxamine or phenylephrine, have not been shown to be more effective. Currently, due to the good experimental results, the use of vasopressin (ADH) in CPR is being evaluated. However there is little (only three studies) and debated evidence based on randomized clinical trials (norepinephrine or ADH) in humans. Once these are reviewed, it can be concluded: The results of the three randomized studies in humans obtain different results regarding the utility of ADH in cardiorespiratory arrest (CRA) secondary to ventricular fibrillation, electro-mechanical dissociation or asystole. More prospective studies are needed to know the role of ADH in prolonged CRA and in asystole, that may be the subgroups that can benefit the most from this drug. The neurological repercussion of a drug in the context of CRA should be evaluated before its inclusion in the CPR guides.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiopulmonary Resuscitation I: Adult
Cardiopulmonary Resuscitation III: AED Use
Cardiopulmonary Resuscitation II: ACLS Airway Management
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Heart Failure VI: Adjunct Therapies

